# INFECTIVE ENDOCARDITIS

## RISK FACTORS

1. RHD - developing countries
2. Prosthetic Valve and cardiac devices
3. congenital heart disease - mainly mitral valve prolapse, developed countries - degenerative cardiac lesions
4. injectable drug use 
5. hiv
6. extensive health care system contact

## ORGANISMS

1. staph 30-40%
2. strep 30% - mainly viridans
3. enterococci - 10%
4. coNS 9%
5. culture negative - 9%
6. HACEK group - 2 %
7. fungal - 2%
8. Non - infective - marantic, libman sachs ie

## ORGAN SPECIFIC PATHOLOGY

### HEART

1. vegetations - in the line of closure of valve leaflet on the atrial surface of av valves or on the ventricular surface of semilunar valves 
2. perforations
3. rupture of chordae tendinae, iv septum or papillary muscle 
4. valve ring abscess with fistula formation in myocardium or pericardial sac - s.aureus
5. MI - embolic complications - mainly in aortic valve IE

### RENAL 
1. emboli - infarction
2. septic emboli - abscess
3. septic emboli - immune complex glomerulonephritis - abscess

### NEUROVASCULAR
1. mycotic aneurysms - mainly in bifurcation points - mostly in cerebral vessels

### SPLENIC MANIFESTATIONS 
1. splenic infacts
2. splenomegaly - mostly seen in q fever and viridans streptococci IE 

### PULMONARY COMPLICATIONS:
1. mainly from tricuspid valve, central venous catheters 
2. pneumonia, pleural effusions or empyema 

### SKIN 
1. petechiae 
2. cutaneous infarcts 
3. oslers 
4. janeway lesions (osler vs janeway = tender non intimal inflammations(immune) vs non-tender, (infective) subcutaneous hemorrhages 

### OCULAR
1. Roth spots - immune
2. Endophthalmitis - inflammatory

## DIAGNOSIS

Clinical, Microbiological, Radiological(echo)

1. Clinical 
	- fever 
	- murmurs 
	- chest pain - emboli lung
	- immunological vascualar phenomenon of skin, brain etc.
2. Microbiology
	- **blood culture - most important**
	- serology for q fever, murine typhus, psittacosis, bartonella, chlamydia, mycoplasma, legionella pneumophila
	- pcr of cardiac valve tissues
3. Echocardiography 	
	- second most important
	- trans esophageal gt trans thoracic

**MODIFIED DUKES CRITERIA - CURRENT GOLD STANDARD**

## TREATMENT
- based on blood culture
- empiric antibiotics - **vancomycin**
- treatment duration of native valve IE(NVIE) - 2 weeks - 6 weeks
- treatment duration of prosthetic valve IE(PVIE) - 6 weeks 
- treatment same for both NVIE and PVIE except staph PVIE - add rifampicin and gentamicin 
- treatment of cardiac implantable devices - remove device - use the same antibiotics
- staph - only vanco, dapto, cephalo, penicillins -- no genta and rifampicin - 6 weeks 
- cons - coagulase negative staph - same as above
- strep - penicillins, cephalo with genta - 2 weeks
- enterococci - ampi + ceftriaxone(if genta resistance)/genta, if vre(rare) - linezolid/daptomycin
- HACEK (hemophilus sp., aggregatibacter sp., cardiobacgerium hominis, eikenella corrodens, kingella sp.) - ampicilins for 4 weeks 
- fungal (rare) - prognosis bad, surgery 
- avoid anticoagulation(causes cerebral hemorrhage)
